+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Malignant Ascites Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767423
  • Report
  • April 2019
  • Region: Global
  • 55 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Fresenius SE & Co KGaA
  • Hangzhou Converd Co Ltd
  • Kazia Therapeutics Ltd
  • MRC Biotech Pty Ltd
  • MORE
The global clinical trial report- “2019 Malignant Ascites Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Malignant Ascites. It presents in-depth analysis of Malignant Ascites clinical trials across markets and companies. The research work is for providing complete understanding into trends in Malignant Ascites.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Malignant Ascites clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Malignant Ascites

The research work is prepared through extensive and continuous research on Malignant Ascites trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Malignant Ascites patients are identified
  • The report includes panorama of Malignant Ascites clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Malignant Ascites clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Fresenius SE & Co KGaA
  • Hangzhou Converd Co Ltd
  • Kazia Therapeutics Ltd
  • MRC Biotech Pty Ltd
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Malignant Ascites Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Malignant Ascites Clinical Trials by Region
2.2.2 Average Enrollment of Malignant Ascites Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Malignant Ascites Treatment, 2019

3. Region wise Malignant Ascites Clinical Trials
3.1 Asia Pacific Malignant Ascites Clinical Trials by Country
3.2 Europe Malignant Ascites Clinical Trials by Country
3.3 North America Malignant Ascites Clinical Trials by Country
3.4 Middle East and Africa Malignant Ascites Clinical Trials by Country
3.5 South and Central America Malignant Ascites Clinical Trials by Country

4. Malignant Ascites Clinical Trial Trends
4.1 Start Year wise Malignant Ascites Clinical Trials
4.2 Phase wise Malignant Ascites Clinical Trials
4.3 Trial Status wise Malignant Ascites Clinical Trials
4.4 Trial Type wise Malignant Ascites Clinical Trials

5. Malignant Ascites Average Enrollment Trends
5.1 Average Enrollment in Malignant Ascites Trials by Year
5.2 Average Enrollment in Malignant Ascites Trials by Phase
5.3 Average Enrollment in Malignant Ascites Trials by Status
5.4 Average Enrollment in Malignant Ascites Trials by Type of Trial

6. Companies Participating in Malignant Ascites Clinical Trials
6.1 Malignant Ascites Trials by Sponsor Type
6.2 Malignant Ascites Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Malignant Ascites Trials- Phase 1
7.2 Malignant Ascites Trials- Phase 2
7.3 Malignant Ascites Trials- Phase 3
7.4 Malignant Ascites Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Malignant Ascites Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Malignant Ascites Clinical Trials and Enrolment
Figure 5: Europe - Country wise Malignant Ascites Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Malignant Ascites Clinical Trials and Enrolment
Figure 7: North America - Country wise Malignant Ascites Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Malignant Ascites Clinical Trials and Enrolment
Figure 9: Malignant Ascites Clinical Trials by Phase
Figure 10: Malignant Ascites Clinical Trials by Trial Status
Figure 11: Malignant Ascites Clinical Trials by Type
Figure 12: Malignant Ascites Clinical Trials by Sponsor Type
Figure 13: Malignant Ascites Clinical Trials by Leading Sponsors
Figure 14: Malignant Ascites Average Enrollment by Phase
Figure 15: Malignant Ascites Average Enrollment by Trial Status
Figure 16: Malignant Ascites Average Enrollment by Type
Figure 17: Malignant Ascites- Average Enrolment by Type of Sponsors
Figure 18: Malignant Ascites- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Malignant Ascites Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Malignant Ascites Clinical Trials and Enrolment
Table 5: Europe - Country wise Malignant Ascites Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Malignant Ascites Clinical Trials and Enrolment
Table 7: North America - Country wise Malignant Ascites Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Malignant Ascites Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Malignant Ascites Average Enrollment by Phase
Table 15: Malignant Ascites Average Enrollment by Trial Status
Table 16: Malignant Ascites Average Enrollment by Type
Table 17: Malignant Ascites- Average Enrolment by Type of Sponsors
Table 18: Malignant Ascites- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Fresenius SE & Co KGaA
  • Hangzhou Converd Co Ltd
  • HealthCare Global Enterprises Ltd
  • Kazia Therapeutics Ltd
  • MRC Biotech Pty Ltd
  • Neopharm Ltd
  • Regeneron Pharmaceuticals Inc
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll